Consequently, the CTLA-4 pathway is a critical component of immune-based cancer therapies and treatments for autoimmune diseases and CTLA-4 deficiency (29). This evidence concerns the gene CTLA4 and hyperinsulinemic hypoglycemia, familial, 4.